Welcome to Abbott's fourth quarter 2024 earnings conference call. [Operator instructions] This call is being recorded by ...

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...

Abbott Laboratories (NYSE:ABT) reported its Q3 2024 earnings, meeting EPS expectations while slightly missing revenue forecasts. The company posted an EPS of $1.34, aligning with analysts' predictions ...

Abbott (ABT) is one of the stocks most watched ... And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward.

It's also important for investors to be aware of any recent modifications to analyst estimates for Abbott. These recent revisions tend to reflect the evolving nature of short-term business trends.

Mike Comilla-- Vice President, Investor Relations Good morning ... are the 10 best stocks for investors to buy now… and Abbott Laboratories wasn’t one of them. The 10 stocks that made the ...

investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term ...

Danielle Antalffy; Analyst; UBS Securities LLC Matt Miksic; Analyst; Barclays Capital Inc.

It cannot be recorded or rebroadcast without Abbott’s express written permission. I would now like to introduce Mr. Mike Comilla, Vice President, Investor Relations. Good morning and thank you ...